Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10‐year intention‐to‐treat analysis
Min Woo Lee, Steven S. Raman, Nazanin H. Asvadi, Surachate Siripongsakun, Robert M. Hicks, Jeffrey Chen, Akeanong Worakitsitisatorn, Justin McWilliams, Myron J. Tong, Richard S. Finn, Vatche G. Agopian, Ronald W. Busuttil, David S.K. Lu – 7 February 2017 – In a long‐term (10‐year) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver transplantation (LT), we evaluated the impact of RFA on waiting list dropout rate, post‐LT tumor recurrence, and long‐term intention‐to‐treat, disease‐specific survival (DSS).